Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064753 · ClinicalTrials.gov registry record · Phase 2
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
A Phase 2 study of Cardiovascular Disease and Chronic Kidney Disease, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 4,110
- Enrollment target
- 20
- Study locations
NCT00064753: Completed Phase 2 study of Cardiovascular Disease and Chronic Kidney Disease, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT00064753 is a Phase 2 study of Cardiovascular Disease and Chronic Kidney Disease that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 4,110 participants, above the 2,667-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (54% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00064753, a Phase 2 study of Cardiovascular Disease and Chronic Kidney Disease, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4,110 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this randomized clinical trial is to determine if lowering homocysteine levels in renal transplant recipients with a multivitamin will reduce the occurrence of cardiovascular disease outcomes.
Conditions Studied
Interventions
- DRUG High Dose Multivitamin
- DEVICE Low Dose Multivitamin
Study Locations (20)
California
- Cedars-Sinai Health System/Center for Kidney Diseases and Transplantation - Los Angeles
- University of California at Los Angeles - Los Angeles
- University of California at San Francisco - San Francisco
Minnesota
- Hennepin County Medical Center - Minneapolis
- Faireview University Medical Center - Minneapolis
- Mayo Clinic - Rochester
Illinois
- Northwestern University - Chicago
- Southern Illinois University - Springfield
New York
- Albany Medical Center - Albany
- State University of New York Downstate Medical Center - Brooklyn
Alabama
- University of Alabama at Birmingham School of Medicine - Birmingham
Arizona
- Banner Good Samaritan Transplant - Phoenix
Indiana
- Indiana University - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,110 participants |
| Start Date | 2002-05 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
What the finished NCT00064753 record still lists
NCT00064753 is an interventional study that assigns participants to a tested intervention. Its 4,110 participants enrollment target places it among the larger protocols in the corpus, above the 2,667-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (54% higher).
The record links to 3 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which High Dose Multivitamin is the first listed.
NCT00064753 names 20 study sites across 14 states, led by California, Minnesota, Illinois.
Frequently Asked Questions
What is clinical trial NCT00064753 about?
NCT00064753 is a clinical study titled "Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)". The purpose of this randomized clinical trial is to determine if lowering homocysteine levels in renal transplant recipients with a multivitamin will reduce the occurrence of cardiovascular disease outcomes.
What is the current status of trial NCT00064753?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4,110 participants. The study started on 2002-05. Estimated completion is 2011-10.
What conditions does trial NCT00064753 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Chronic Kidney Disease, Death.
What interventions are being tested in trial NCT00064753?
The interventions under investigation include: High Dose Multivitamin (DRUG), Low Dose Multivitamin (DEVICE).
Who is sponsoring clinical trial NCT00064753?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00064753 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00064753's enrollment target sits among peer trials
4,110 19th of 137 higher than 119 of 137 other Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
Metformin in Kidney Disease
COMPLETED · Phase 2
-
Biomarker Guided Therapies in Stage A/B Heart Failure
COMPLETED · Phase 2
-
Reduction of Smoking in Cardiac Disease Patients
COMPLETED · Phase 2
-
The Fibrin Pad Cardiovascular Study
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03388606 · 4,100 participants
Characterization and Treatment of Adolescent Depression
- NCT06593353 · 4,165 participants · NA
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
- NCT02693535 · 4,200 participants · Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- NCT05969028 · 4,200 participants · NA
First Responder Airway & Compression Rate Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia